

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. In the randomized Phase III POLO trial evaluating maintenance olaparib versus placebo in patients with germline *BRCA1/2* mutated pancreatic cancer, which of the following outcomes have been reported with olaparib?

 - a. Improvement in overall survival but not progression-free survival
 - b. Improvement in progression-free survival but not overall survival
 - c. Improvement in both progression-free survival and overall survival
 - d. No improvement in either overall survival or progression-free survival
2. Which of the following was the most commonly reported adverse event among patients receiving olaparib in the POLO trial?

 - a. Nausea
 - b. Anorexia
 - c. Fatigue
3. Which of the following best reflects the frequency of mutations within DNA damage response and repair genes in patients with pancreatic adenocarcinomas?

 - a. 2% to 6%
 - b. 17% to 25%
 - c. 31% to 40%
4. Which of the following immunotherapies is being tested in combination with olaparib in a Phase II trial currently enrolling patients with pancreatic cancer who have germline *BRCA1/2* or *PALB2* mutations and a partial response at best to first line therapy?

 - a. Pembrolizumab
 - b. Dostarlimab
 - c. Nivolumab
 - d. Ipilimumab